Navigation Links
European Hospital Anticoagulant Market Dominated by Sanofi-Aventis's Clexane

MALVERN, Pa., Sept. 28 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that more than half of all European inpatients who receive anticoagulants during their hospital stay are administered Sanofi-Aventis's Clexane (marketed as Lovenox in the U.S. and France).

The new audit entitled The European Hospital Anticoagulant Market Guide is a comprehensive source for anticoagulant use in European hospitals. Released quarterly, the audit contains detailed clinical data from thousands of hospitalized patients receiving anticoagulants. Survey results are projected to the national level for France, Germany, Italy, Spain and the United Kingdom.

The audit also reveals that surgical venous thromboembolism (VTE) primary prophylaxis accounts for the largest share of inpatient anticoagulant use at 48 percent of all inpatients. However, non-surgical VTE and stroke prophylaxis remains a key area of growth opportunity for companies marketing and developing anticoagulant agents.

The European Hospital Anticoagulant Market Guide is designed to help biopharmaceutical companies quantify targeted patient segments, better understand treatment practices and customers, size commercial opportunity and formulate clinical development strategy.

Besides Clexane, Boehringer Ingelheim's Pradaxa, Bayer's Xarelto and all other anticoagulants used in European hospitals are tracked in this audit.

About AMR

AMR ( serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

SOURCE Arlington Medical Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
2. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
3. Metabolic Solutions Development Company to Present Research Findings to European Association for the Study of Diabetes
4. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
5. Tibotec Pharmaceuticals Seeks European Marketing Authorization for Investigational Once-Daily HIV Treatment TMC278
6. European Interspinous Process Decompression Device Market Will Grow Nominally at 1.2% over the Next Five Years
7. For Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabTheras Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
8. Mindray Medical to Present at the Goldman Sachs 7th Annual European Medtech and Healthcare Services Conference
9. Sunridge Schedules European Meetings
10. European Patent Office Upholds GlideScope® Video Laryngoscope Patent
11. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
Post Your Comments:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... Research and Markets has announced the ... report to their offering. ... favourable commercial environment for MedImmune to enter. The US ageing ... serve to drive considerable growth for effective anti-influenza medications. The ... sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has dedicated ... has implemented orthobiologic procedures as a method for treating his patients. The procedure ... doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
Breaking Medicine News(10 mins):